Estrella Immunopharma (ESLA) said Friday it has completed the first dose group in its ongoing phase I/II clinical trial evaluating EB103 in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Based on preliminary data, no dose-limiting toxicities or serious adverse events related to treatment were observed in the group, with tumor response noted in all patients in the first month, the company said.
After reviewing safety and efficacy data, the Data and Safety Monitoring Board has approved the initiation of a higher dose group, the company added.
The company's shares were up 4% in recent trading.
Price: 1.55, Change: +0.06, Percent Change: +4.03
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.